Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Nagaendran Kandiah, Ming-Chyi Pai, Vorapun Senanarong, Irene Looi, Encarnita Ampil, Kyung Won Park, Ananda Krishna Karanam & Stephen Christopher. (2017) Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia. Clinical Interventions in Aging 12, pages 697-707.
Read now
Read now
Secundino López-Pousa & Francisco Javier Arranz. (2013) Characteristics of patients with Alzheimer’s disease who switch to rivastigmine transdermal patches in routine clinical practice. Patient Preference and Adherence 7, pages 47-54.
Read now
Read now
Martin R. Farlow, George Grossberg, Serge Gauthier, Xiangyi Meng & Jason T. Olin. (2010) The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Current Medical Research and Opinion 26:10, pages 2441-2447.
Read now
Read now
Articles from other publishers (41)
Zhiming Li, Puxuan Zhao, Zhixin Ling, Yanting Zheng, Fengli Qu & Hao Chang. (2023) An Ultraswelling Microneedle Device for Facile and Efficient Drug Loading and Transdermal Delivery. Advanced Healthcare Materials.
Crossref
Crossref
Ashvin VaradharajanAarjith Damian DavisAishwarya GhoshTejaswini JagtapAnjo XavierAnjana Jayakumar MenonDwaiti RoySandhya GandhiThomas Gregor. (2023) Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs. Journal of Neurosciences in Rural Practice 14, pages 566-573.
Crossref
Crossref
SNEH PRIYA, DIVYA JYOTHI & CYNTHIA LIZZIE LOBO. (2023) DEVELOPMENT AND CHARACTERIZATION OF PLANT OIL-BASED POTENT ANTICHOLINESTERASE MICROEMULSION CONTAINING WITHANIA SOMNIFERA EXTRACT WITH ENHANCED TRANSDERMAL DELIVERY OF PHYTOCONSTITUENTS FOR THE TREATMENT OF COGNITIVE DISORDERS. International Journal of Applied Pharmaceutics, pages 166-172.
Crossref
Crossref
Wenqi Gao, Xiaohong Ma, Huijuan Yang, Yuxia Luan & Hongqi Ai. (2022) Molecular engineering and activity improvement of acetylcholinesterase inhibitors: Insights from 3D-QSAR, docking, and molecular dynamics simulation studies. Journal of Molecular Graphics and Modelling 116, pages 108239.
Crossref
Crossref
Mohammad Saeedi & Fatemeh Mehranfar. (2022) Challenges and Approaches of Drugs Such as Memantine,
Donepezil, Rivastigmine, and Aducanumab in the Treatment,
Control and Management of Alzheimer's Disease. Recent Patents on Biotechnology 16:2, pages 102-121.
Crossref
Crossref
Yan Yang, Jia-jun Zhao & Xue-feng Yu. (2022) Expert Consensus on Cognitive Dysfunction in Diabetes. Current Medical Science 42:2, pages 286-303.
Crossref
Crossref
Zhi Xin Phuna & Priya Madhavan. (2022) A closer look at the mycobiome in Alzheimer's disease: Fungal species, pathogenesis and transmission. European Journal of Neuroscience 55:5, pages 1291-1321.
Crossref
Crossref
Hyun Jeong Han, Mee Young Park, Kyung Won Park, Kee Hyung Park, Seong Hye Choi, Hee-Jin Kim, Dong Won Yang, Esther Gunaseli Ebenezer, Yuan-Han Yang, Gurudev M. Kewalram & Seol-Heui Han. (2022) A Multinational, Multicenter, Randomized, Double-Blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer’s Disease. Journal of Clinical Neurology 18:4, pages 428.
Crossref
Crossref
Shawn D X Kong, Camilla M Hoyos, Craig L Phillips, Andrew C McKinnon, Pinghsiu Lin, Shantel L Duffy, Loren Mowszowski, Haley M LaMonica, Ronald R Grunstein, Sharon L Naismith & Christopher J Gordon. (2021) Altered heart rate variability during sleep in mild cognitive impairment. Sleep 44:4.
Crossref
Crossref
Rashid Waseem, Anas Shamsi, Taj Mohammad, Fahad A. Alhumaydhi, Syed Naqui Kazim, Md. Imtaiyaz Hassan, Faizan Ahmad & Asimul Islam. (2021) Multispectroscopic and Molecular Docking Insight into Elucidating the Interaction of Irisin with Rivastigmine Tartrate: A Combinational Therapy Approach to Fight Alzheimer’s Disease. ACS Omega 6:11, pages 7910-7921.
Crossref
Crossref
Lalit K. Vora, Kurtis Moffatt, Ismaiel A. Tekko, Alejandro J. Paredes, Fabiana Volpe-Zanutto, Deepakkumar Mishra, Ke Peng, Raghu Raj Singh Thakur & Ryan F. Donnelly. (2021) Microneedle array systems for long-acting drug delivery. European Journal of Pharmaceutics and Biopharmaceutics 159, pages 44-76.
Crossref
Crossref
Immacolata Vecchio, Luca Sorrentino, Annamaria Paoletti, Rosario Marra & Mariamena Arbitrio. (2021) The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease. Journal of Central Nervous System Disease 13, pages 117957352110291.
Crossref
Crossref
Vesna Jelic & Bengt Winblad. 2021. Management of Patients with Dementia. Management of Patients with Dementia
73
104
.
Marcos Pais, Luana Martinez, Octávio Ribeiro, Júlia Loureiro, Romel Fernandez, Leandro Valiengo, Paulo Canineu, Florindo Stella, Leda Talib, Marcia Radanovic & Orestes V. Forlenza. (2020) Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges. Brazilian Journal of Psychiatry 42:4, pages 431-441.
Crossref
Crossref
Anas Shamsi, Taj Mohammad, Saleha Anwar, Mohamed F. Alajmi, Afzal Hussain, Md. Imtaiyaz Hassan, Faizan Ahmad & Asimul Islam. (2020) Probing the interaction of Rivastigmine Tartrate, an important Alzheimer's drug, with serum albumin: Attempting treatment of Alzheimer's disease. International Journal of Biological Macromolecules 148, pages 533-542.
Crossref
Crossref
Othman A. Al Hanbali, Haji Muhammad Shoaib Khan, Muhammad Sarfraz, Mosab Arafat, Shakeel Ijaz & Abdul Hameed. (2019) Transdermal patches: Design and current approaches to painless drug delivery. Acta Pharmaceutica 69:2, pages 197-215.
Crossref
Crossref
Seyed Vahid Mousavi & Seyed Majid Hashemianzadeh. (2018) Poly (n-butyl cyanoacrylate) as a nanocarrier for rivastigmine transport across the blood–brain barrier in Alzheimer’s disease treatment: a perspective from molecular dynamics simulations. Journal of Molecular Modeling 24:9.
Crossref
Crossref
Rita Khoury, Jayashree Rajamanickam & George T. Grossberg. (2018) An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine. Therapeutic Advances in Drug Safety 9:3, pages 171-178.
Crossref
Crossref
Bongsoo Kim, Keum-Yong Seong, Insang You, Veerapandian Selvaraj, Sang-Gu Yim, Eoin D. O’Cearbhaill, Unyong Jeong & Seung Yun Yang. (2018) Touch-actuated transdermal delivery patch for quantitative skin permeation control. Sensors and Actuators B: Chemical 256, pages 18-26.
Crossref
Crossref
Preeti Wavikar, Rohan Pai & Pradeep Vavia. (2017) Nose to Brain Delivery of Rivastigmine by In Situ Gelling Cationic Nanostructured Lipid Carriers: Enhanced Brain Distribution and Pharmacodynamics. Journal of Pharmaceutical Sciences 106:12, pages 3613-3622.
Crossref
Crossref
Naresh Mittapelly, Maharshi Thalla, Gitu Pandey, Venkatesh Teja Banala, Shweta Sharma, Abhishek Arya, Sandeep Mishra, Kalyan Mitra, Shubha Shukla & Prabhat Ranjan Mishra. (2017) Long Acting Ionically Paired Embonate Based Nanocrystals of Donepezil for the Treatment of Alzheimer’s Disease: a Proof of Concept Study. Pharmaceutical Research 34:11, pages 2322-2335.
Crossref
Crossref
Alice Simon, Maria Inês Amaro, Anne Marie Healy, Lucio Mendes Cabral & Valeria Pereira de Sousa. (2017) Development of a Discriminative In Vitro Release Test for Rivastigmine Transdermal Patches Using Pharmacopeial Apparatuses: USP 5 and USP 6. AAPS PharmSciTech 18:7, pages 2561-2569.
Crossref
Crossref
Nuggehally R. Srinivas. (2016) Transdermal Rivastigmine Delivery for Alzheimer Disease: Amenability of Exposure Predictions of Rivastigmine and Metabolite, NAP226-90, by Linear Regression Model Using Limited Samples. Clinical Neuropharmacology 39:4, pages 169-177.
Crossref
Crossref
Hyeyun KimHyun Jeong Han. (2016) The Effect of Rivastigmine Transdermal Patch on Sleep Apnea in Patients with Probable Alzheimer's Disease. Dementia and Neurocognitive Disorders 15:4, pages 153.
Crossref
Crossref
Sven Stegemann. 2016. Developing Drug Products in an Aging Society. Developing Drug Products in an Aging Society
279
290
.
G. Alva, J. L. Cummings, J. E. Galvin, X. Meng & D. M. Velting. (2015) Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease. International Journal of Clinical Practice 69:5, pages 518-530.
Crossref
Crossref
A.J. Cruz Jentoft & B. Hernández. (2014) Rivastigmine as treatment for patients with mild to moderately severe Alzheimer disease under normal clinical practice conditions. The ENTERPRISE study. Neurología (English Edition) 29:1, pages 1-10.
Crossref
Crossref
A.J. Cruz Jentoft & B. Hernández. (2014) Manejo terapéutico con rivastigmina en pacientes con enfermedad de Alzheimer de leve a moderadamente grave en condiciones de práctica clínica habitual. Estudio ENTERPRISE. Neurología 29:1, pages 1-10.
Crossref
Crossref
Merc? Boada & Francisco Javier Arranz. (2013) Transdermal Is Better than Oral: Observational Research of the Satisfaction of Caregivers of Patients with Alzheimer?s Disease Treated with Rivastigmine. Dementia and Geriatric Cognitive Disorders 35:1-2, pages 23-33.
Crossref
Crossref
A. Trebbastoni, F. Gilio, F. D?Antonio, C. Cambieri, M. Ceccanti, C. de Lena & M. Inghilleri. (2012) Chronic treatment with rivastigmine in patients with Alzheimer?s disease: A study on primary motor cortex excitability tested by 5Hz-repetitive transcranial magnetic stimulation. Clinical Neurophysiology 123:5, pages 902-909.
Crossref
Crossref
Joonho Choi, Min-Koo Choi, Saeho Chong, Suk-Jae Chung, Chang-Koo Shim & Dae-Duk Kim. (2012) Effect of fatty acids on the transdermal delivery of donepezil: In vitro and in vivo evaluation. International Journal of Pharmaceutics 422:1-2, pages 83-90.
Crossref
Crossref
Andrea Bershow & Erin Warshaw. (2011) Cutaneous Reactions to Transdermal Therapeutic Systems. Dermatitis 22:4, pages 193-203.
Crossref
Crossref
Hyun Jeong HanJeong Ju LeeSun A. ParkHyun Young ParkJeong Eun KimYoung Soo ShimDong-Seok ShimEun-Joo KimSoo Jin YoonSeong Hye Choi. (2011) Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease. Journal of Clinical Neurology 7:3, pages 137.
Crossref
Crossref
Ken Nagata, Daiki Takano, Takashi Yamazaki, Tetsuya Maeda, Yuichi Satoh & Taizen Nakase. (2011) 2. Pharmacological Treatment of Dementia.2．薬物療法. Nihon Naika Gakkai Zasshi 100:8, pages 2134-2145.
Crossref
Crossref
Murat Emre, Roberto Bernabei, Rafael Blesa, Roger Bullock, Luis Cunha, Hugo Daniëls, Edward Dziadulewicz, Hans Förstl, Lutz Frölich, Tomasz Gabryelewicz, Oleg Levin, James Lindesay, Pablo Martínez‐Lage, Andreas Monsch, Magda Tsolaki & Teus Van Laar. (2010) Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease. CNS Neuroscience & Therapeutics 16:4, pages 246-253.
Crossref
Crossref
G. T. Grossberg, C. Sadowsky & J. T. Olin. (2010) Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer’s disease. International Journal of Clinical Practice 64:5, pages 651-660.
Crossref
Crossref
C. Sadowsky, J.A. Davila Perez, R.W. Bouchard, I. Goodman & S. Tekin. (2010) Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch. CNS Neuroscience & Therapeutics 16:1, pages 51-60.
Crossref
Crossref
Jeffrey L. Cummings, Martin R. Farlow, Xiangyi Meng, Sibel Tekin & Jason T. Olin. (2010) Rivastigmine Transdermal Patch Skin Tolerability. Clinical Drug Investigation 30:1, pages 41-49.
Crossref
Crossref
David Cunningham Owens. 2010. Companion to Psychiatric Studies. Companion to Psychiatric Studies
227
294
.
. (2009) Current awareness in geriatric psychiatry. International Journal of Geriatric Psychiatry 24:7.
Crossref
Crossref
A. Kurz, M. Farlow & G. Lefèvre. (2009) Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review. International Journal of Clinical Practice 63:5, pages 799-805.
Crossref
Crossref